| |
All patients (n = 37) |
Patients with FeNO<37 ppb (n = 25) |
Patients with FeNO ≥37 ppb (n = 12) |
p-Value |
| Age (years) |
61(49-69) |
61(39-68) |
65(53-70) |
0.3379 |
| Gender, male/female |
15/22 |
10/15 |
5/7 |
0.9230 |
| Body mass index (kg/m2) |
23.0(19.4-25.4) |
23.4(19.4-26.1) |
21.9(19.7-24.6) |
0.6037 |
| Atopic/nonatopic |
27/10 |
18/7 |
9/3 |
0.8475 |
| Non/ex-smokers |
29/8 |
20/5 |
9/3 |
0.7295 |
| Duration of asthma, years |
5.0(1.0-14.0) |
5.0(2.0-16.0) |
4.5(1.0-10.0) |
0.2032 |
| Coexisting allergic rhinitis |
16 |
8 |
8* |
0.0463 |
| ACQ5, overall score |
0.0(0.0-0.2) |
0.0(0.0-0.2) |
0.0(0.0-0.1) |
0.5040 |
| FVC, L |
3.14(2.58-3.70) |
3.02(2.43-3.44) |
3.47(2.67-4.05) |
0.2427 |
| %FVC (% predicted) |
106.2(88.6-113.5) |
97.9(88.0-109.6) |
115.8(104.6-134.2) |
0.0071 |
| FEV1, L |
2.38(1.80-2.91) |
2.36(1.80-2.91) |
2.43(1.86-2.97) |
0.6731 |
| %FEV1 (% predicted) |
89.4(80.6-108.2) |
88.2(80.6-105.1) |
106.2(79.1-112.0) |
0.2561 |
| %FEF50%(% predicted) |
63.1(43.3-94.2) |
64.0(47.8-102.9) |
57.7(40.0-91.9) |
0.3636 |
| %FEF75%(% predicted) |
45.5(29.0-76.6) |
46.5(34.8-81.1) |
37.4(25.8-62.5) |
0.1630 |
| PEF variability, % |
3.3(2.0-4.8) |
3.3(2.0-5.7) |
2.7(1.8-4.6) |
0.6063 |
| Min%Max PEF, % |
90.2(87.7-93.0) |
90.3(87.1-93.0) |
90.0(87.8-94.8) |
0.8539 |
| FeNO, ppb |
28.0(18.5-38.5) |
20.0(18.0-28.0) |
51.5(40.8-57.5) |
<0.0001 |
Data are expressed as the medians (interquartile ranges).
Abbreviations: ACQ5: Asthma Control Questionnaire, 5-item version; FEF50%:Forced Expiratory Flow at 50% of FVC; FeNO: Fractional Exhaled Nitric Oxide; FEV1:Forced
Expiratory Volume In 1 Second; FVC:Forced Vital Capacity;Min%Max PEF:The Lowest PEF over A Week Expressed as the Percentage of the Highest PEF; PEF:Peak
Expiratory Flow.*p <0.05 versus patients with FeNO<37 ppb. |
